

TRADEMARK ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
Name	Formerly	Execution Date	Entity Type
US Worldmeds, LLC		09/20/2012	LIMITED LIABILITY COMPANY: DELAWARE
<b>RECEIVING PARTY DATA</b>			
Name:	JPMorgan Chase Bank, N.A.		
Street Address:	1300 East Ninth Street		
Internal Address:	13th Floor		
City:	Cleveland		
State/Country:	OHIO		
Postal Code:	44114		
Entity Type:	National Banking Association: UNITED STATES		
<b>PROPERTY NUMBERS Total: 2</b>			
Property Type	Number	Word Mark	
Registration Number:	3871489	REVONTO	
Registration Number:	2973482	APOKYN	
<b>CORRESPONDENCE DATA</b>			
Fax Number:	2163634588		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	216.363.4635		
Email:	trademark@beneschlaw.com		
Correspondent Name:	Malisheia O. Douglas		
Address Line 1:	Benesch Friedlander Coplan & Aronoff LLP		
Address Line 2:	200 Public Square, Suite 2300		
Address Line 4:	Cleveland, OHIO 44114		
ATTORNEY DOCKET NUMBER:	35553.2		
NAME OF SUBMITTER:	Malisheia O. Douglas		

OP \$65.00 3871489

Signature:	/Malisheia O. Douglas/
Date:	09/24/2012
<b>Total Attachments: 6</b> source=Notice of Security Interest - US WorldMeds, LLC#page1.tif source=Notice of Security Interest - US WorldMeds, LLC#page2.tif source=Notice of Security Interest - US WorldMeds, LLC#page3.tif source=Notice of Security Interest - US WorldMeds, LLC#page4.tif source=Notice of Security Interest - US WorldMeds, LLC#page5.tif source=Notice of Security Interest - US WorldMeds, LLC#page6.tif	

NOTICE OF SECURITY INTEREST

US WORLDMEDS, LLC, a Delaware limited liability company (together with its successors and assigns, "Pledgor"), and JPMORGAN CHASE BANK, N.A., ("Lender") are parties to a certain Amended and Restated Pledge and Security Agreement dated as of the date hereof ("Security Agreement").

WHEREAS, Pledgor owns certain rights, title and interest in and to certain Copyrights, Patents and Trademarks (as defined in the Security Agreement), including the Copyrights, Patents and Trademarks listed on the annexed Schedule A attached hereto; and

WHEREAS, Pledgor has granted Lender a security interest as set forth in the Security Agreement in and to, among other things, all right, title and interest of Pledgor in the Copyrights, Patents and Trademarks, to secure the payment, performance and observance of certain obligations defined in the Security Agreement.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Pledgor does hereby grant to the Lender a security interest in the Copyrights, Patents and Trademarks to secure the prompt payment, performance and observance of the obligations defined in the Security Agreement.

Lender does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Copyrights, Patents and Trademarks made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein.

*Signature Page Follows*



**SCHEDULE A**  
**TO**  
**NOTICE OF SECURITY INTEREST**

**Copyrights**

None.

**Patents**

See attached Schedule A-1

**Trademarks**

See attached Schedule A-2.

**SCHEDULE A-1**

**PATENTS**

UNITED STATES

TITLE	SERIAL NO.	FILED	REG. NO.	REG. DATE
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents	12205303	9/5/08		
Compositions and methods for transmucosal delivery of lofexidine	12410114	3/24/09		
Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery	12999659	12/17/10		
Intranasal delivery system for dantrolene	13266358	10/26/11		
Transdermal delivery of apomorphine using microneedles*	13060118	2/22/11		

\*No assignment from inventors to US WorldMeds on file

FOREIGN

TITLE	COUNTRY/ JURISDICTION	REG. NO./APP. NO.
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents	Canada	2702243
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents	European Patent Convention	088370796
Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents	Japan	2010-528917
Composition and method for transmucosal delivery of lofexidine	European	097246508
Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery	European	097710099
Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery	European	110022241
Transdermal delivery of apomorphine using microneedles	European	0980887011217

**SCHEDULE A-2**

**TRADEMARKS**

UNITED STATES

MARK	SERIAL NO.	FILED	REG. NO.	REG. DATE
REVONTO	77880100	11/24/09	3871489	11/2/10
APOKYN	78269572	7/2/03	2973482	7/19/05

FOREIGN

MARK	COUNTRY/ JURISDICTION	REG. NO./APP. NO.
MYOBLOC	Canada	TMA809909
MYOBLOC	Republic of Korea	40-0783616
NERBLOC (Roman and Katakana)	Japan	4983424
NEUROBLOC	Benelux	782785
NEUROBLOC	Canada	TMA516043
NEUROBLOC	European Community	611384
NEUROBLOC	Iceland	6752000
NEUROBLOC	Norway	203409
NEUROBLOC	Switzerland	476705
NEUROBLOC	Turkey	2002009753
REVONTO	European Community	009008137
SOLSTICENEURO	Benelux	781112

***NOTICE OF SECURITY INTEREST (INTELLECTUAL PROPERTY)- CHASE/US  
WORLDMEDS - US WORLDMEDS, LLC***